Related company info
Ingrid Lee, Taipei; Steve Shen, DIGITIMES
Monday 19 November 2012
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$32.8 on the TSE on Thursday, January 18, 2018.
    The company has reported consolidated revenues of NT$156 million for December 2017, representing a 9.7% increase on month and 62.2% increase on year.
    For the third quarter of 2017, the company totaled NT$478 million in consolidated revenues, up 14% sequentially and up 18.7% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$985.31 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    19-Jan 321 252 10,435,160 32.85 33.00 32.35 32.45-0.35-1.07% 32.45 32.50
    18-Jan 366 260 11,991,686 32.95 33.00 32.70 32.80+0.15+0.46% 32.75 32.80
    17-Jan 788 495 26,074,800 33.50 33.70 32.65 32.65-0.70-2.10% 32.65 32.85
    16-Jan 854 593 28,269,050 32.55 33.50 32.50 33.35+1.00+3.09% 33.30 33.35
    15-Jan 313 234 10,081,200 32.25 32.35 31.95 32.35+0.30+0.94% 32.30 32.35
    12-Jan 191 153 6,116,259 32.30 32.40 31.95 32.05-0.15-0.47% 32.05 32.15
    11-Jan 165 124 5,318,800 32.40 32.40 32.00 32.20+0.20+0.63% 32.05 32.25
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Dec 2016 - Dec 2017 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Dec-17

    156

    9.7%

    62.2%

    1,795

    1.8%

    Nov-17

    143

    (17.7%)

    3.2%

    1,639

    (1.7%)

    Oct-17

    173

    12.6%

    28.8%

    1,496

    (2.1%)

    Sep-17

    154

    5.4%

    17.5%

    1,323

    (5.1%)

    Aug-17

    146

    (18.4%)

    19.3%

    1,169

    (7.4%)

    Jul-17

    179

    16.7%

    19.1%

    1,024

    (10.3%)

    Jun-17

    153

    17.6%

    (4.5%)

    845

    (14.8%)

    May-17

    130

    (4.6%)

    (21.7%)

    692

    (16.7%)

    Apr-17

    136

    (22.2%)

    (25.2%)

    561

    (15.5%)

    Mar-17

    175

    77.6%

    (6.2%)

    425

    (11.8%)

    Feb-17

    99

    (34.6%)

    (25.8%)

    250

    (15.4%)

    Jan-17

    151

    56.6%

    (6.9%)

    151

    (6.9%)

    Dec-16

    96

    (30.2%)

    (30.2%)

    1,763

    (4.6%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2018

    Apex: Consolidated revenues, 3Q16 - 3Q17 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    3Q-17

    478

    14%

    18.7%

    1,323

    (5.1%)

    2Q-17

    420

    (1.2%)

    (17.5%)

    845

    (14.8%)

    1Q-17

    425

    15.2%

    (11.8%)

    425

    (11.8%)

    4Q-16

    369

    (8.5%)

    (23.1%)

    1,763

    (4.6%)

    3Q-16

    403

    (20.8%)

    (14.3%)

    1,394

    1.9%

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2018

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 3Q16 - 3Q17 (NT$k)

    Item

    3Q-2017

    2Q-2017

    1Q-2017

    4Q-2016

    3Q-2016

    Current assets

    1,576,999

    1,632,388

    1,647,085

    1,602,788

    1,783,928

    Intangible assets

    304,638

    314,386

    25,010

    25,854

    26,609

    Non-current assets

    1,124,705

    1,143,758

    880,663

    897,998

    1,075,070

    Assets

    2,701,704

    2,776,146

    2,527,748

    2,500,786

    2,858,998

    Current liabilities

    1,062,660

    818,230

    482,436

    414,574

    642,761

    Non-current liabilities

    17,492

    355,661

    354,649

    353,912

    355,451

    Liabilities

    1,080,152

    1,173,891

    837,085

    768,486

    998,212

    Stockholders' equity

    1,621,552

    1,602,255

    1,690,663

    1,732,300

    1,860,786

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2018

    Apex: Consolidated income statement, 3Q16 - 3Q17 (NT$k)

    Item

    3Q-2017

    2Q-2017

    1Q-2017

    4Q-2016

    3Q-2016

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Gross sales

    478,449

     

    419,801

     

    424,990

     

     

     

    403,241

     

    Operating revenue

    478,449

    100%

    419,801

    100%

    424,990

    100%

    368,972

    91.5%

    403,241

    100%

    Gross profit (loss) from operations

    102,951

    21.5%

    89,252

    21.3%

    75,548

    17.8%

    89,255

    22.1%

    91,021

    22.6%

    Operating expenses

    77,552

    16.2%

    47,662

    11.4%

    60,894

    14.3%

    56,217

    13.9%

    55,379

    13.7%

    Operating income (loss)

    25,399

    5.3%

    41,590

    9.9%

    14,654

    3.4%

    33,038

    8.2%

    35,642

    8.8%

    Non-operating expenses and losses

    3,629

    0.8%

    19,106

    4.6%

    -53,646

    -12.6%

    -144,637

    -35.9%

    -34,016

    -8.4%

    Income from continuing operations before income tax

    29,028

    6.1%

    60,696

    14.5%

    -38,992

    -9.2%

    -111,599

    -27.7%

    1,626

    0.4%

    Net income (loss)

    20,501

    4.3%

    57,277

    13.6%

    -38,992

    -9.2%

    -130,469

    -32.4%

    1,245

    0.3%

    Diluted earnings per share (NT$)

    0.2

     

    0

     

     

     

    0

     

    0

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2018

  • Apex Biotechnology full profile

Taiwan handsets – 3Q 2017

China smartphone AP shipments – 3Q 2017

China smartphone market and industry – 3Q 2017

Taiwan server shipment forecast and industry analysis, 2018

China AMOLED panel capacity expansion forecast, 2016-2020

Taiwan server shipment forecast and industry analysis, 2017

© DIGITIMES Inc. All rights reserved.
Please do not republish, publicly broadcast or publicly transmit content from this website without written permission from DIGITIMES Inc. Please contact us if you have any questions.